Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | The impact of hemophilia inhibitors on patient outcomes

Melissa Bou Jaoudeh • 11 Jul 2022
ISTH 2022
Hemophilia Emicizumab

Melissa Bou Jaoudeh, PhD, Sorbonne University, Paris, France, highlights some of the challenges in the management of patients with hemophilia with inhibitors, discussing the influence of bypassing agents on artieral and venous thrombotic events, and emphasizing the importance of eradicating inhibitors in this patient population. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK

More from Melissa Bou Jaoudeh

1:36
Unmet needs in hemophilia: guidelines for emicizumab & better therapeutics for hemophilia A
Melissa Bou Jaoudeh • 11 Jul 2022
1:39
Therapeutic potential of IdeS in hemophilia A with inhibitors
Melissa Bou Jaoudeh • 11 Jul 2022

Related Videos

1:08
The current landscape of hemophilia treatment: an update from ASH 2023
Glaivy Batsuli • 10 Dec 2023
1:18
Unmet needs in hemophilia treatment
Glaivy Batsuli • 10 Dec 2023
1:11
Improving outcomes for hemophilia patients through the implementation of gene therapies
Evelien Krumb • 12 Dec 2023
1:27
The impact of emicizumab on the hemophilia treatment landscape
Glaivy Batsuli • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals